- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Bristol-Myers Squibb Company(BMY)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for BMY
11/20/2026: BMY (3-star) is a WEAK-BUY. BUY for 5 days. Simulated Profits (-6.56%). Updated daily EoD!
Bristol-Myers Squibb Company is a major global biopharmaceutical enterprise specializing in oncology, immunology, cardiovascular, and neuroscience therapies. The company's primary strength lies in its fast-expanding growth portfolio—featuring blockbusters like Opdivo, Camzyos, and Breyanzi—which successfully offsets declines in legacy products. Its core investment appeal centers on steady cash flow generation, a reliable dividend history, and an innovative pipeline targeting specialty care. However, the company faces substantial risks from impending patent cliffs on older drugs and intense biopharmaceutical competition. The stock suits value and dividend-focused investors seeking steady income while monitoring clinical trial catalysts and pipeline execution.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | While the growth portfolio expands rapidly, legacy patent expirations temper overall corporate top-line expansion speed. |
| Momentum investor | Strong fit while signal remains positive | Momentum appeal depends closely on positive clinical trial readouts and commercial beats from new product launches. |
| Value investor | Strong fit | The stock often trades at a modest valuation multiple relative to earnings, supported by solid cash flow generation. |
| Dividend investor | Strong fit | A consistent history of dividend growth and a high yield make it attractive for income-focused portfolios. |
| Low-risk investor | Mixed fit | Steady pharmaceutical demand provides defensive characteristics, though binary clinical trial and patent risks introduce volatility. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium | Biopharmaceutical stocks can experience short-term swings driven by regulatory decisions and clinical data readouts. |
| Valuation risk | Low / none | Reasonable earnings multiples limit excessive valuation downside compared to high-flying growth sectors. |
| Competition risk (name the main competitor theme, e.g. AI competition) | Medium / high | Intense rivalry from major competitors like Merck and Pfizer threatens market share across core therapeutic categories. |
| Business quality | Strong | The company maintains a high-quality global franchise with entrenched scientific capabilities and strong operating margins. |
| Dividend income | Low | The dividend is well-supported by stable cash flows and an established track record of consecutive annual raises. |
| Execution risk | Medium / high | Successfully replacing declining legacy revenues with pipeline blockbusters is critical for long-term stability. |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 120.19B USD | Price to earnings Ratio 13.04 | 1Y Target Price 65.25 |
Price to earnings Ratio 13.04 | 1Y Target Price 65.25 | ||
Volume (30-day avg) 11.5M shares | Beta 0.19 | 52 Weeks Range 45.55 - 67.94 | Updated Date 11/21/2026 |
52 Weeks Range 45.55 - 67.94 | Updated Date 11/21/2026 | ||
Dividends yield (FY) 4.32% | Basic EPS (TTM) 4.51 |
Sector & Industry Intelligence
Sector
Healthcare
Constructive- Sentiment
- Strong Bullish
- Momentum
- BUY Breadth Improving
- BUY participation
- 55.2%
- Active BUY / eligible
- 53 / 96
- 30-Day BUY Count Change
- +19
- Market state
- Strong Bullish
More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.
Industry
Drug Manufacturers - General
- BUY participation
- 90.0%
- Active BUY / eligible
- 9 / 10
- 30-Day BUY Count Change
- +3
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Rolling Over
The price momentum is slowing down and beginning to turn downward.

Smooth
The stock has moved along a generally orderly path with only modest fluctuations.
Analysis of Past Performance
Type Stock | Historic Profit 23.3% | Avg. Invested days 41 | Today’s Advisory WEAK BUY |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Oncology and Immuno-Oncology | Global sales of flagship cancer therapies including Opdivo, Opdualag, and cellular therapies like Breyanzi. | This is the primary growth engine and largest revenue pillar for the company. |
| Cardiovascular and Specialty Care | Sales from blockbuster blood thinner Eliquis, heart medication Camzyos, and hematology product Reblozyl. | Provides massive baseline cash flow despite looming patent challenges on older blockbusters. |
| Geographic Markets | Commercial operations spanning the United States, Europe, and international markets. | The United States remains the largest revenue contributor, supplemented by a diversified global footprint. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-10-29 | When Before Market | Estimate 1.21 | Actual 1.35 |
Profitability
Profit Margin 18.47% | Operating Margin (TTM) 32.37% |
Management Effectiveness
Return on Assets (TTM) 10.9% | Return on Equity (TTM) 44.01% |
Valuation
Trailing PE 13.04 | Forward PE 8.87 | Enterprise Value 152.42B | Price to Sales(TTM) 2.4 |
Enterprise Value 152.42B | Price to Sales(TTM) 2.4 | ||
Enterprise Value to Revenue 3.05 | Enterprise Value to EBITDA 9.66 | Shares Outstanding 2.04B | Shares Floating 2.04B |
Shares Outstanding 2.04B | Shares Floating 2.04B | ||
Percent Insiders 0.1 | Percent Institutions 85.44 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

